May #123 : Women on Top - by Rebecca Minnich

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 
One Tough Pirate



Seeing the Future

Mentors-May 2006

Medicine Men




Custom Care

Early Birds

Simply Irresistible

The Topic of Cancer

Sow Your Oats

Trainer’s Bench-May 2006

Hustle and Flow

Animal Attraction

Purrrfect Health

Women on Top

PEP Rally

POZ Personals Catch of the Month-May 2006

First Aid for Your Medicaid

Shall We Dance?




A Will & Grace-full Exit?

Ratings for a Serial Virus

Squeaky Clean?

Prescription For Change

Bono’s Red Alert

One Hot ASO

Banned Aid

It’s Not You; It’s Me

Near Dead Again




Editor's Letter-May 2006

Mailbox-May 2006



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV



email print

May 2006


Women on Top

by Rebecca Minnich

An HIV gel slides toward FDA approval

Microbicides would allow ladies to control their own sexual safety, without depending on men to wear a condom and avoid unsafe sex on the side. Though activists have pushed the products as a funding and research priority since 1990, not one has been approved—prompting charges that the medical establishment ignores women’s safety. (It’s an equal-opportunity offender: No gels for men exist either.) In January, however, the Food and Drug Administration put the HIV-blocking vaginal microbicide VivaGel on what it dubs its “fast track” to approval. Fast-track status means that the FDA will speed the review of all findings. It doesn’t mean more funds will be pumped into VivaGel’s development. The manufacturer, Starpharma, hopes for approval as early as 2008. Anna Forbes from the Global Campaign for Microbicides, says, “2008 is very optimistic. VivaGel hasn’t entered Phase III [human] trials yet.”

VivaGel is the second microbicide to be fast tracked (the first was in 2003 and is still in Phase III  trials), and dozens more are creeping up the pipeline. “It’s good news, but we need to move the whole pipeline forward,” Forbes adds. “Nobody knows which one is going to work.”

Global funds for microbicides more than doubled from $66 million in 2000 to $163 million in 2005. “We had several microbicides in advanced trials, and people noticed that women now make up the majority of new infections. It caused a shift in public discourse,” says Forbes. “But we still have only half the funding we need.” The International Partnership for Microbicides recently received a $30 million grant, but the organization’s Joseph Romano, MD, says it needs $100 million more by 2007 to get even one microbicide through Phase III trials. And then, hopefully, fast track a sexual revolution.     


[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dlw8585
    Fort Lauderdale
    Florida


    soy_Ric
    Rochester
    New York


    usuallyhappy
    Palm Springs
    California


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been tested for hepatitis C?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.